深化产学研融合，北京大学携手云南白药绘就发展新图景

Core Insights - The Chinese biopharmaceutical industry is experiencing a dual benefit of increased policy support and accelerated industrial upgrades, with a focus on high-quality development driven by technological breakthroughs and deep integration of industry, academia, and research [2][3] - Yunnan Baiyao, as a leading traditional Chinese medicine enterprise, is actively engaging in innovation and transformation, leveraging its resource integration capabilities and academic collaboration to connect industry needs with research outcomes [2][3] Industry Developments - The "2025 Pharmaceutical Innovation and Technology Frontier Forum" was held in Kunming, co-hosted by Peking University and Yunnan Baiyao, attracting over 500 experts to discuss advancements in oncology, reproductive medicine, trauma orthopedics, and oral medicine [2] - Yunnan Baiyao aims to collaborate with top global research institutions to focus on drug development, clinical trials, and translational medicine, enhancing core technology breakthroughs and the commercialization of research outcomes [3][4] Collaborative Models - The Peking University-Yunnan Baiyao Medical Center exemplifies successful industry-academia collaboration, emphasizing the importance of integrating research and application to enhance the pharmaceutical industry's core competitiveness [3][4] - The center's collaborative model focuses on three main aspects: complementary advantages, resource alignment, and co-creation, aiming to build a world-class medical research center [4] Research and Development Strategies - The core value of industry-academia collaboration lies in effective "outcome transformation," requiring a complete closed-loop mechanism from problem identification to joint research and industrial validation [5] - Yunnan Baiyao is advancing its traditional medicine projects through clinical and foundational research, with significant progress in products like Qixuekang oral liquid, which has shown notable cardiovascular health benefits [6] International Expansion - Yunnan Baiyao is addressing the challenge of insufficient evidence for traditional Chinese medicine in international markets by implementing a differentiated strategy, initially focusing on Southeast Asia and Belt and Road countries [7] - The company emphasizes the need for standardization, scientific validation, and clear communication of active components to align with international standards [7] Innovation in Drug Development - Yunnan Baiyao is expanding its innovative drug portfolio, focusing on nuclear medicine, biopharmaceuticals, and chemical drugs, with several projects achieving significant milestones [8][9] - The company maintains a balanced strategy of licensing and independent research, gradually building its R&D capabilities while leveraging collaborations with top experts and institutions [9][10]